Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$516000.0.

  • Cartesian Therapeutics' Gains from Investment Securities rose 9089.79% to -$516000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 million, marking a year-over-year increase of 7112.63%. This contributed to the annual value of -$2.6 million for FY2024, which is 7993.1% up from last year.
  • Per Cartesian Therapeutics' latest filing, its Gains from Investment Securities stood at -$516000.0 for Q3 2025, which was up 9089.79% from -$654000.0 recorded in Q2 2025.
  • Cartesian Therapeutics' 5-year Gains from Investment Securities high stood at $16.7 million for Q1 2021, and its period low was -$18.5 million during Q1 2022.
  • Moreover, its 5-year median value for Gains from Investment Securities was -$1.0 million (2024), whereas its average is -$1.9 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first surged by 187955.08% in 2021, then tumbled by 23645.36% in 2023.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Gains from Investment Securities stood at -$9.0 million in 2021, then tumbled by 50.66% to -$13.6 million in 2022, then soared by 50.59% to -$6.7 million in 2023, then soared by 103.66% to $245000.0 in 2024, then plummeted by 310.61% to -$516000.0 in 2025.
  • Its last three reported values are -$516000.0 in Q3 2025, -$654000.0 for Q2 2025, and -$1.8 million during Q1 2025.